Skip NavigationSkip to Content

The development of beta-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides: enabling practical multi-gram syntheses of 4'-Thio-2'-deoxycytidine (T-dCyd) and 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd) to support clinical development

  1. Author:
    Wishka,Donn
    Lopez,Omar
    Rudchenko, Vladimir F.
    Huang, Guangfei
    Bahde, Robert
    Kumar, Vineet
    Denysenko, Sergiy M.
    Zhang, Lianhao
    Zhang, Mianji
    Teicher, Beverly A.
    Morris, Joel
  2. Author Address

    NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Rockville, MD USA.Alchem Labs Corp, Alachua, FL USA.Frederick Natl Lab Canc Res, Bldg 322,Room 104, Frederick, MD 21702 USA.
    1. Year: 2020
    2. Date: OCT 15
  1. Journal: NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
  2. TAYLOR & FRANCIS INC,
  3. Type of Article: Article
  4. ISSN: 1525-7770
  1. Abstract:

    The lack of effective methods to perform direct beta-selective glycosylation reactions with 2-deoxy-1,4-dithio-D-erythro-pentofuranosides has long been a significant stumbling block for the multi-gram synthesis of 4'-thio-2'-deoxy nucleosides. In addition, previously reported methods for the preparation of appropriately substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides have proven problematic for large scale synthesis. To address these issues, herein we describe the modification and optimization of previously reported methods to allow for the convenient large scale synthesis of benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides. Furthermore, we describe the development of reaction conditions for beta-selective glycosylation reactions of benzyl substituted 2-deoxy-1,4-dithio-D-erythro-pentofuranosides with both N4-benzoylcytosine and 5-aza-cytosine to enable the practical multi-gram syntheses of the clinical candidates 4'-thio-2'-deoxycytidine (T-dCyd) and 5-aza-4'-thio-2'-deoxycytidine (aza-T-dCyd). Taken together, these new synthetic developments have made possible the preclinical and early clinical development of these important anticancer agents at the National Cancer Institute.

    See More

  1. Keywords:

External Sources

  1. DOI: 10.1080/15257770.2020.1832694
  2. WOS: 000578043000001

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel